Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Moxifloxacin
Drug ID BADD_D01501
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D08237
MeSH ID D000077266
PubChem ID 152946
TTD Drug ID D0ZV0Z
NDC Product Code 65977-0038; 51407-321; 63629-8357; 0378-5430; 65862-840; 72189-321; 16714-643; 50090-6357; 55111-112; 70518-3713; 80425-0239; 50090-5833; 53002-2723; 68180-421; 61919-553; 72789-233; 60505-0582; 68180-422; 72189-334; 17478-519; 31722-845; 0904-6406; 12527-0517; 50090-3147
UNII U188XYD42P
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H24FN3O4
CAS Registry Number 151096-09-2
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adverse event08.06.01.010---
Cardiac disorder02.11.01.003---
Oral fungal infection07.05.07.009; 11.03.05.010---
Decreased appetite08.01.09.028; 14.03.01.005--
Psychotic disorder19.03.01.002--
Immunosuppression10.03.02.001---
Hyperlipidaemia14.08.03.001--
Renal impairment20.01.03.010---
Increased upper airway secretion22.12.03.007---
Infusion site extravasation08.02.05.007; 12.07.05.008--
Vulvovaginal mycotic infection11.03.05.004; 21.14.02.004---
Ulcerative keratitis06.04.02.004; 10.02.01.0210.000808%
Ventricular tachyarrhythmia02.03.04.012---
Suicidal behaviour19.12.01.006---
Tendon pain15.07.01.009---
Oropharyngeal pain07.05.05.004; 22.12.03.016--
Acute kidney injury20.01.03.016--
Bilirubin conjugated decreased13.03.04.013---
Candida infection11.03.03.021--
Depersonalisation/derealisation disorder19.14.01.004---
Pharyngeal hypoaesthesia17.02.06.034; 22.04.05.017---
Anterior chamber disorder06.06.07.0020.000269%-
Tongue discomfort07.14.02.019---
Hypersensitivity pneumonitis10.01.03.056; 22.01.01.027---
Iris transillumination defect06.06.06.0090.000431%-
Pharyngeal swelling22.04.05.028---
Reaction to excipient10.01.01.0420.000135%-
Sinus pain22.12.03.023--
Brain fog16.32.03.050; 17.02.05.077; 19.21.02.017---
The 11th Page    First    Pre   11    Total 11 Pages